Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spire Health Closed A $38M Financing Round To Expand Commercialization Of Respiratory Remote Patient Monitoring Platform

Executive Summary

Spire Health plans to use its new financing to expand commercialization of its respiratory remote patient monitoring platform, which combines AI with sensors in “health tags” worn inside clothing.

You may also be interested in...



Digital Health Roundup, July 2021: Exec Chat With DTA, Start-Ups Grab New Funds, Agency Nods

In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from July.

Market Brief: New Triple-Combination Therapies Help Boost Lackluster Inhalation Devices Market

The inhalation devices market will reach $12bn by 2023, driven by the rising prevalence of asthma and COPD worldwide. GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim dominate worldwide sales of inhalation products for asthma and COPD, and are facing generic competition. Generics developers and major pharma players are trying to set themselves apart with better drug-delivery devices. 

Digital Health Roundup: Cardio Smart Watches, Pear Therapeutics Own 'Reset,' Agetech Boom

In this month’s Digital Health roundup, Medtech Insight’s Reed Miller talks about iRhythm and Withings’ smartwatches business, Barnaby Pickering reviews digital therapeutics Pear Therapeutics’ restructuring, and Marion Webb presents highlights from her new series on Agetech.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT144215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel